Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

NCT03480152 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

NIH

Sponsor class

Stopped slow accrual

Conditions

Melanoma
Colon Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Hepatocellular Cancer

Interventions

BIOLOGICAL: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine

Sponsor

National Cancer Institute (NCI)